Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation
Denmark, March 26, 2018 /PRNewswire/ -- Genmab A/S (CPH: GEN, OTC:GMXAY), focused on the creation and development of differentiated antibody therapeutics for the treatment of cancer, today announced that their
Genmab A/S' presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the virtual trade booth in the Exhibits section of the event.
About Genmab A/SGenmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEXŪ (daratumumab) for the treatment of certain multiple myeloma indications, and ArzerraŪ (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBodyŪ platform for generation of bispecific antibodies, and the HexaBodyŪ platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
View original content:http://www.prnewswire.com/news-releases/genmab-as-webcast-presentation-now-available-for-on-demand-viewing-dbvic---deutsche-bank-adr-virtual-investor-conference-300619201.html
SOURCE Genmab A/S
Subscribe to our Free Newsletters!